LEXX Stock Overview
Operates as a biotechnology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Lexaria Bioscience Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.09 |
| 52 Week High | US$6.85 |
| 52 Week Low | US$1.20 |
| Beta | 1.06 |
| 11 Month Change | -21.13% |
| 3 Month Change | -27.93% |
| 1 Year Change | 59.54% |
| 33 Year Change | -60.86% |
| 5 Year Change | -84.52% |
| Change since IPO | -36.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| LEXX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.0% | 1.6% | 2.2% |
| 1Y | 59.5% | 9.9% | 31.6% |
Return vs Industry: LEXX exceeded the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: LEXX exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| LEXX volatility | |
|---|---|
| LEXX Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LEXX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LEXX's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | Rich Christopher | lexariabioscience.com |
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.
Lexaria Bioscience Corp. Fundamentals Summary
| LEXX fundamental statistics | |
|---|---|
| Market cap | US$36.48m |
| Earnings (TTM) | -US$4.85m |
| Revenue (TTM) | US$411.02k |
88.7x
P/S Ratio-7.5x
P/E RatioIs LEXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEXX income statement (TTM) | |
|---|---|
| Revenue | US$411.02k |
| Cost of Revenue | US$4.82k |
| Gross Profit | US$406.20k |
| Other Expenses | US$5.26m |
| Earnings | -US$4.85m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 98.83% |
| Net Profit Margin | -1,179.96% |
| Debt/Equity Ratio | 0% |
How did LEXX perform over the long term?
See historical performance and comparison